secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2024-01-03T23:59:59+00:00
Accession:  0001628280-24-000123
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion settles litigation with Daiichi Sankyo Europe for $125M; receives $100M near-term
--------------------------------------------------------------------------------

- Daiichi Sankyo Europe to pay Esperion $100M by mid-January 2024 and additional $25M after EMA decision on NILEMDO/NUSTENDI label expansion.
- Parties dismiss pending litigation in Southern District of New York.
- Esperion transitions manufacturing/supply to DSE; DSE leads EMA regulatory communications.
- Collaboration expanded to include triple combination pill (bempedoic acid/ezetimibe/statin).
- Esperion eligible for up to $300M commercial milestones (DSE territory) and up to $175M (DS territory) plus tiered royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024000123/0001628280-24-000123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024000123/espr-20240102.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-000123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer